Monitoring Disease Markers in Children with Acute Lymphoblastic Leukaemia
Author Information
Author(s): Suchandra Chowdhury, Suman Bandyopadhyay, Chandan Mandal, Sarmila Chandra, Chitra Mandal
Primary Institution: Indian Institute of Chemical Biology
Hypothesis
Can the expression of 9-O-acetylated sialoglycoproteins and known CD antigens be used to monitor minimal residual disease in children with acute lymphoblastic leukaemia?
Conclusion
The study suggests that monitoring minimal residual disease using specific templates can help predict relapse in children with acute lymphoblastic leukaemia.
Supporting Evidence
- 81.65% of patients remained in clinical remission during the study.
- MRD detection levels reached as low as 0.01% in patients in clinical remission.
- Failure to clear lymphoblasts early in treatment indicated a higher risk of relapse.
Takeaway
Doctors can check for tiny amounts of cancer cells in kids with leukemia to see if they might get sick again, even if they seem healthy.
Methodology
A two-year longitudinal study monitored 109 patients using flow cytometry to detect minimal residual disease in peripheral blood and bone marrow.
Limitations
The study was limited to a specific treatment protocol and may not be generalizable to all populations.
Participant Demographics
Median age of participants was 6 years, with a male to female ratio of 2:1.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website